Key opinion leaders (KOLs) are health care leaders who make a high-impact footprint while advancing medical science. Thought Leader Select specializes in delivering objective, validated data on the skills and experiences of KOLs, so that pharmaceutical companies can seek their appropriate advice and guidance in the development of new medicines.
Thought Leader Select measures many areas where KOLs leave their respective marks in the medical community, including conducting clinical research studies, publishing articles in leading journals, and presenting breakthrough knowledge at scientific conferences.
In a recent assessment of over 300 North American specialists in atrial fibrillation, Thought Leader Select measured the frequency of these global key opinion leaders’ respective participation in regulatory and reimbursement activities. Using keywords to link these KOLs with such activities covering a six-year period, Thought Leader Select found that only 50 of the 300 physicians had any significant, relevant experience related to regulatory and reimbursement issues, such as participation on Pharmacy and Therapeutics Committees, FDA Advisory Boards, etc.
While the overall pool of 300 medical experts in atrial fibrillation showed significant diversity in skills and experience in a variety of areas, there are only a small number of these experts that have any experience in regulatory and reimbursement issues. Pharmaceutical companies wishing to seek consultative advice from these highly specialized thought leaders need to find effective ways to differentiate these experts from other general key opinion leaders.